Detalhe da pesquisa
1.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
2.
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.
Lancet Oncol
; 24(3): 228-238, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36858721
3.
Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial.
Int J Cancer
; 153(6): 1241-1250, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294085
4.
Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001.
Int J Gynecol Cancer
; 32(1): 93-100, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34799418
5.
Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity.
Cancer Immunol Immunother
; 70(4): 1101-1113, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33123754
6.
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer.
J Gynecol Oncol
; 35(2): e40, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38302725
7.
Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study.
Eur Urol
; 2024 Apr 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38582713
8.
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.
J Clin Oncol
; 42(11): 1222-1228, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38227898
9.
Survivin promotion of melanoma metastasis requires upregulation of α5 integrin.
Carcinogenesis
; 34(9): 2137-44, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23640047
10.
Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study.
Eur Urol Oncol
; 6(4): 437-446, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720658
11.
Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician's Choice.
Eur J Cancer
; 186: 172-184, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37086595
12.
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.
J Clin Oncol
; 41(16): 2904-2910, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37058687
13.
Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1223282, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37664025
14.
Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms.
Front Oncol
; 13: 1343027, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38495081
15.
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.
J Immunother Cancer
; 9(2)2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33589527
16.
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kß Inhibition in PTEN Loss Melanoma.
Clin Cancer Res
; 25(21): 6406-6416, 2019 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31371342
17.
Improving warfarin therapy through implementation of a hospital-based pharmacist managed clinic in Jamaica.
Pharm Pract (Granada)
; 16(4): 1214, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30637024
18.
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
J Natl Cancer Inst
; 110(7): 777-786, 2018 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29267866
19.
The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression.
Clin Cancer Res
; 24(14): 3366-3376, 2018 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29496759
20.
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
Cell Metab
; 27(5): 977-987.e4, 2018 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29628419